Future prospects for alemtuzumab (MabCampathࡊ)

Medical Oncology

Volumn 19, Issue , 2002, Pages S57-S63

  Rai, Kanti ^a   Hallek, Michael ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b Genzentrum der Universitaet MuenchenGSF National Research Center for Health and Environment   (Germany)

Author keywords

Campath 1H, leukemia, B cell; Chronic; Monoclonal antibody

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; CHLORAMBUCIL; CLADRIBINE; COTRIMAZINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; VALACICLOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFECT; DRUG RESPONSE; DYSPNEA; HUMAN; HYPOTENSION; MINIMAL RESIDUAL DISEASE; NAUSEA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RIGOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; B CELL LEUKEMIA; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMAN; LEUKEMIA, B-CELL, CHRONIC; NEOPLASM, RESIDUAL; STEM CELL TRANSPLANTATION; HUMANS;

EID: 0036276657     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:2S:S57     Document Type: Article

References (15)

1. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study
2. In vivo "purging" of residual disease in CLL with Campath-1H
3. Campath-1H therapy in 29 patients with refractory CLL: 'True' complete remission is an attainable goal
4. Quantitative real-time polymerase chain reaction for the core facility using TaqMan and the Perkin-Elmer/Applied Biosystems Division 7700 Sequence Detector
5. Monitoring residual tumor cells in patients with chronic lymphatic leukemia during remission using a newly developed real-time PCR method
6. Campath-1H for minimal residual disease in CLL
7. Campath-1H in B-chronic lymphocytic leukemia: Report on a patient treated thrice in a 3 year period
8. Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy
9. Benefits of repeated courses of alemtuzumab (Campath) in patients with relapsed/refractory B-CLL
10. CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL)
11. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
12. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
13. Campath-1H with fludarabine: A novel, highly active combination in refractory CLL
14. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
15. Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)